P-糖蛋白抑制剂的研究进展  

Advances in Inhibitor of P-Glycoprotein

作　　者：康恺[1] 李运曼[1] 

机构地区：[1]中国药科大学生理教研室,江苏南京210009

出　　处：《药学进展》2004年第9期405-408,共4页Progress in Pharmaceutical Sciences

摘　　要：介绍P 糖蛋白抑制剂的发展、P 糖蛋白抑制剂的特性及第二代和第三代抑制剂的临床应用现状。多药耐药是肿瘤化疗失败原因之一 ,其以P 糖蛋白的过度表达为特征 ,导致化疗药物从癌细胞中的外排增加 ,使疗效降低。因此有效抑制P 糖蛋白的活性可逆转肿瘤的多药耐药性。Multidrug resistance is now recognized as one of the common causes for the failure of cancer chemotherapy. Classic MDR is associated with the overexpression of p-glycoprotein(p-gp), resulting in increased efflux of chemotherapeutic agents from cancer cells and decrement of the therapeutic effect. Therefore, effective inhibiting the activity of p-glycoprotein can be used to reverse the MDR of tumor cells. This article introduces the development of the p-glycoprotein inhibitors, characteristics of 1～3 generation of p-glycoprotein inhibitors, and the clinical trials of the second and third generation of p-glycoprotein inhibitors.

关 键 词：P-糖蛋白抑制剂 肿瘤 多药耐药性 化疗 

分 类 号：R979.1[医药卫生—药品]